MENU
+Compare
CAPR
Stock ticker: NASDAQ
AS OF
Jan 14 closing price
Price
$24.79
Change
-$0.00 (-0.00%)
Capitalization
1.35B

CAPR Capricor Therapeutics Forecast, Technical & Fundamental Analysis

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs... Show more

Industry: #Biotechnology
CAPR
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
a Summary for CAPR with price predictions
Jan 14, 2026

CAPR's Stochastic Oscillator is remaining in oversold zone for 6 days

The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The 50-day moving average for CAPR moved above the 200-day moving average on December 12, 2025. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CAPR advanced for three days, in of 276 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The 10-day RSI Indicator for CAPR moved out of overbought territory on December 30, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 29 similar instances where the indicator moved out of overbought territory. In of the 29 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Momentum Indicator moved below the 0 level on January 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CAPR as a result. In of 81 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for CAPR turned negative on December 24, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CAPR declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CAPR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (16.103) is normal, around the industry mean (27.929). P/E Ratio (0.000) is within average values for comparable stocks, (51.397). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.899). Dividend Yield (0.000) settles around the average of (0.055) among similar stocks. P/S Ratio (101.010) is also within normal values, averaging (329.547).

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

View a ticker or compare two or three
CAPR
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published Earnings

CAPR is expected to report earnings to fall 5.00% to -51 cents per share on March 25

Capricor Therapeutics CAPR Stock Earnings Reports
Q4'25
Est.
$-0.51
Q3'25
Est.
$-0.54
Q2'25
Missed
by $0.09
Q1'25
Missed
by $0.21
Q4'24
Beat
by $0.01
The last earnings report on November 10 showed earnings per share of -54 cents, meeting the estimate of -54 cents. With 1.07M shares outstanding, the current market capitalization sits at 1.35B.
A.I. Advisor
published General Information

General Information

Develops innovative products for the treatment of cardiovascular diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
10865 Road to the Cure
Phone
+1 858 727-1755
Employees
102
Web
https://www.capricor.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FBSIX38.850.21
+0.54%
Franklin Mutual U.S. Mid Cap Value R6
PCVAX12.180.06
+0.50%
Virtus NFJ Small-Cap Value A
TGREX12.490.02
+0.16%
TCW Global Real Estate I
MXVIX44.73N/A
N/A
Empower S&P 500® Index Investor
NRARX56.14-0.27
-0.48%
Neuberger Quality Equity R3

CAPR and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, CAPR has been loosely correlated with VRAX. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if CAPR jumps, then VRAX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CAPR
1D Price
Change %
CAPR100%
N/A
VRAX - CAPR
48%
Loosely correlated
+7.48%
KRRO - CAPR
33%
Loosely correlated
+0.11%
BEAM - CAPR
33%
Poorly correlated
+2.49%
ACLX - CAPR
32%
Poorly correlated
+4.66%
LXEO - CAPR
32%
Poorly correlated
+3.90%
More